Tumor biomarkers, the substances which are produced by tumors or the body's responses to
tumors during tumorigenesis and progression, have been demonstrated to possess critical …

Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …

Cell-free DNA (cfDNA) analysis represents a promising method for the diagnosis, treatment
selection and clinical follow-up of cancer patients. Although its general methodological …

An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Purpose.—Clinical use of analytical tests to assess genomic variants in circulating tumor
DNA (ctDNA) is increasing. This joint review from the American Society of Clinical Oncology …

During cancer progression and treatment, multiple subclonal populations of tumour cells
compete with one another, with selective pressures leading to the emergence of …

Colorectal cancer (CRC) is one of the most common malignancies in Western countries.
Over the last 20 years, and the last decade in particular, the clinical outcome for patients with …

Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor
palbociclib and fulvestrant was associated with significant improvements in progression-free …

Summary Background Phosphatidylinositol 3-kinase (PI3K) pathway activation is a hallmark
of endocrine therapy-resistant, hormone receptor-positive breast cancer. This phase 3 study …

CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with
advanced estrogen receptor-positive breast cancer, although there are no predictive …